Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Talquetamab in Treating Relapsed/Refractory Multiple Myeloma: Insights from an International Immunotherapy Registry Analysis

  • By

  • Murali Janakiram

  • Carlyn R. Tan

  • Hira Mian

  • Chiung-Yu Huang

  • Rakesh Popat

  • Joaquín Martínez-Lopez

  • Efsthathios Kastritis

  • Wee-Joo Chng

  • Prashant Kapoor

  • Mrugakshi Dave

  • Susan Bal

  • Laurent Garderet

  • Andre De Menezes Silva Corraes

  • Christine Riedhammer

  • Torsten Steinbrunn

  • Magdalene Corona

  • Chandramouli Nagarajan

  • Hermann Einsele

  • Tom Martin

  • Amrita Krishnan

  • Yi Lin

  • May 19, 2026

Share

Original Source(s)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

  • by Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung-Yu Huang, Rakesh Popat, Joaquín Martínez-Lopez, Efsthathios Kastritis, Wee-Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin

  • May 19, 2026

Related Content

Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study

Medicaid Expansion and Mortality Among Patients With Colorectal Cancer

Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women